Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy

Tufts University, Бостон, Georgia, United States
JAMA Neurology (Impact Factor: 7.01). 06/2002; 59(5):766-72. DOI: 10.1001/archneur.59.5.766
Source: PubMed

ABSTRACT The optimal treatment of patients with neuropathy associated with IgG monoclonal gammopathy of undetermined significance is unknown. Plasma exchange has been shown to be effective but alternative therapies have not been systematically evaluated.
To report our experience with intravenous immunoglobulin (IVIG) in patients with IgG monoclonal gammopathy of undetermined significance polyneuropathy.
Retrospective review of clinical and electrodiagnostic features of 20 consecutive patients treated with IVIG over an 8-year period.
Academic medical center.
Medical Research Council strength (maximum, 40 points) and sensory (maximum, 26 points) scores, modified Rankin Disability Scale score.
There were 14 men and 6 women (mean age, 65 years; age range, 36-82 years). The mean strength score was 35.6 points and the mean sensory score was 15.8 points prior to therapy. After IVIG therapy, the mean strength score increased by 1.1 points (P =.22) and the sensory score increased by 1.7 points (P =.11). Eight patients (40%) improved by 2 points or more in their motor or sensory score and 1 point or more in the modified Rankin Disability Scale score and were considered IVIG therapy responders. They had a shorter duration of symptoms (P =.03), numb hands (P =.02), and falling episodes (P =.02), and had greater proximal leg weakness (P =.02) compared with nonresponders. In IVIG therapy responders, the ulnar motor conduction velocity was slower, ulnar and peroneal distal motor latencies were prolonged, and the frequency of conduction block was higher (13 of 36 motor nerves in responders vs 6 of 53 in nonresponders, P =.008).
Intravenous immunoglobulin therapy was beneficial in 8 (40%) of our 20 patients with polyneuropathy and IgG monoclonal gammopathy of undetermined significance. Proximal leg weakness, short duration of symptoms, and demyelinating features on electrodiagnostic studies were associated with a response to IVIG therapy.

  • Practical Neurology 04/2006; 6(2):102-110. DOI:10.1136/jnnp.2006.089433
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction In the past decade, intravenous immunoglobulins (IVIG) have been widely used and their administration has grown throughout the world. The current indications of IVIG in neurological diseases are discussed on the basis of the passed and current trials. Unlike other immuomodulatory agents, IVIG are well tolerated and have very few side effects and a good viral safety. State of art There is clinical evidence, based on controlled trials, for the effectiveness of IVIG in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal neuropathy with conduction blocks. In myasthenia gravis, the IVIG are effective especially in myasthenic crisis, but their synergistic effect with other treatments, the steroid sparing effect, and their long-term effect are unknown. These issues need to be addressed in further controlled clinical trials. In dermatoploymyositis, IVIG are reserved for steroid resistant patients. There is actually no support or no significant clinical benefit for the routine use of IVIG in other neurological diseases. Perspectives Further controlled trials are warranted to assess the quality of life, the dose-finding effect and their long-term efficacy in order to improve clinical practices. Conclusion Routine use of IVIG should be reserved for diseases in which positive controlled trials are available. For the remaining dysimmune diseases, IVIG should be assess in comparison with the other available therapies, taking into consideration the age of the patients, the safety of the IVIG and, in our country, the economic aspect.
    Revue Neurologique 09/2005; 161(8):781-794. DOI:10.1016/S0035-3787(05)85137-9 · 0.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zu verschiedenen neurologischen Autoimmunerkrankungen gibt es für hoch dosierte i. v. Immunglobuline (IVIg) inzwischen überzeugende Ergebnisse aus den nach modernen Standards durchgeführten, plazebokontrollierten Therapiestudien. Dennoch sind sie bei neurologischen Erkrankungen lediglich für das Guillain-Barré-Syndrom zugelassen. Es muss daher ein gezielter Einsatz von IVIg gefordert werden, da eine wirksame Therapie dem Patienten nicht vorenthalten werden darf, insbesondere wenn IVIg nicht durch gleichwertige Alternativen ersetzt werden können. Die hier vorgelegte Arbeit repräsentiert und gewichtet die verfügbaren Studienergebnisse zum Einsatz von IVIg. Auf der Basis dieser Evidenz wurden Empfehlungen zur Therapie mit IVIg erarbeitet, die auf einem breiten Konsens einer international ausgewiesenen, deutschsprachigen Neurologengruppe basieren. Dadurch soll zukünftig ein gezielter Einsatz von IVIg bei neurologischen Autoimmunerkrankungen gewährleistet werden.
    Der Nervenarzt 01/2004; 75(8). DOI:10.1007/s00115-004-1733-4 · 0.86 Impact Factor